Array BioPharma and Biogen Idec Collaborate on Kinase Inhibitors - - BioPharm International

ADVERTISEMENT

Array BioPharma and Biogen Idec Collaborate on Kinase Inhibitors


Array BioPharma will collaborate with Biogen Idec for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.  The collaboration target and lead inhibitors were discovered through Array's proprietary Kinase-Directed Phenotypic Screening Platform.  

"We are encouraged by the potential of this program to address inflammatory disease and are excited to add it to our immunology research portfolio," said Jo Viney, vice-president of Immunology Research, Biogen Idec.

Under the terms of the agreement, Biogen and Array will collaborate on the discovery of the novel kinase inhibitors. Biogen will be responsible for all aspects of clinical development and commercialization. The agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.

Source: Array Biopharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines

Click here